Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Straynut who wrote (12722)	4/15/2020 2:27:34 AM
From: HardToFind	Read Replies (1) \| Respond to of 12871

The company recently developed antiviral drug testing assays and acquired two low-threat circulating coronaviruses to test its SARS-CoV-2 drug candidates in its BSL-2 lab. This in-house testing doesn't require USAMRIID. Do you have any idea how long would it take to get in-vitro results on those two low-threat circulating coronaviruses? I seem to recall that Brian has been able to turn around informal results in as little as a few weeks. Is that right?

To: Straynut who wrote (12722)	4/15/2020 7:32:16 AM
From: old 'n cranky	1 Recommendation Recommended By Savant Respond to of 12871

In addition to HIV, avian influenza, and Ebola, the company has previously worked on nanoviricides for the MERS coronavirus that first emerged in 2014. Yet no NanoViricides drug has ever undergone a clinical trial and successfully treated a single patient for any of those things. Their mention alone is shameful. One thing that their mention should highlight for thinking readers is the likelihood of NNVC's success in developing a COVID-19 treatment....it's not likely at all.